Skip to content
Screener

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Eli Lilly logo
Eli LillyLLY
31.6×-6.7×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×
Wave Life Sciences logo
Wave Life SciencesWVE
2.5×-5.2×
Prime Medicine logo
Prime MedicinePRME
16.7×+12.1×
Perspective Therapeutics logo
Perspective TherapeuticsCATX
1.2×+0.1×

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$798.6M+307%
Enterprise value$746.28M+378%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Calculated from Monopar Therapeutics’s reported figures.

Based on the most recent quarter.

The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 2:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-016982

FAQ

What is Monopar Therapeutics's price / book?
Monopar Therapeutics (MNPR) reported price / book of 2.7× in Q1 2026.
How has Monopar Therapeutics's price / book changed year-over-year?
Monopar Therapeutics's price / book decreased by 34.7% year-over-year, from 4.1× to 2.7×.
What is the long-term trend for Monopar Therapeutics's price / book?
Over 5 years (2020 to 2025), Monopar Therapeutics's price / book has grown at a -33.6% compound annual growth rate (CAGR), from 24.6× to 3.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Monopar Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude